The latest thoracic oncology news
75 per cent drop in UK urgent lung cancer referrals during lockdown say experts
The number of people urgently referred to a lung cancer specialist dropped by 75 percent…
Browsing: Lung Cancer
Efavirenz induces DNA damage response pathway in lung cancer
The cover for Issue 41 of Oncotarget features Figure 7, “IPA ATM-signaling pathway in (A) EFV treated MRC-5 and…
MiR-708-5p targets oncogenic prostaglandin E2 production in lung cancer cell
As reported in volume 11, Issue 26 of Oncotarget, Lung cancer is of particular importance. It…
Potential drug treatment for particular type of lung-cancer
The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is…
NRXN1 as a novel potential target for small cell lung cancer
Research by Yotsumoto, et al. reported that the authors identified transmembrane proteins overexpressed specifically in…
Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers…
New vulnerability found in lung squamous cancer may facilitate drug targeting
New cancer research by scientists at University of North Carolina Lineberger Comprehensive Cancer Center, USA,…
ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer
The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal…
ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and…
FDA approves pralsetinib for lung cancer with RET gene fusions
The Food and Drug Administration granted accelerated approval to pralsetinib for adult patients with metastatic…